Mylan (MYL) Miss Overshadowed by Mediocre Deal - Guggenheim

Mylan (MYL) Shares Look to Stabilize After Pounding on 'Desparate' Meda Deal

February 11, 2016 11:09 AM EST

Mylan (NASDAQ: MYL) is attempting to stabilize as investors express disappointment with the Meda deal, sending the stock in free-fall. Analysts called the deal,... More

RBC Capital Views Mylan's (MYL) Meda Purchase as Desperate - PT to $58

February 11, 2016 8:05 AM EST

RBC Capital reiterated a Sector Perform rating on Mylan (NASDAQ: MYL), and cut the price target to $58.00 (from $60.00), following the company's announcement that they will acquire Meda for $9.9 billion. Separately, MYL missed 4Q. Neither will help the stock and this deal feels desperate in RBC's... More

Mylan to buy Swedish drugmaker Meda in $7.2 billion deal

February 10, 2016 4:49 PM EST

By Natalie Grover

(Reuters) - Generic drugmaker Mylan NV (NASDAQ: MYL) said it would acquire Meda AB in a $7.2 billion cash-and-stock deal in its third attempt to buy the Swedish company.

The move comes three months after Mylan gave up on its seven-month-long pursuit of smaller rival Perrigo (NYSE: PRGO).

Mylan's stock fell about 8 pct in extended trading, after it announced the 165 Swedish crowns per share offer. That works out to be nearly twice Meda's last traded price, which had some analysts... More

Mylan (MYL) Misses Q4 EPS by 5c

February 10, 2016 4:13 PM EST

Mylan (NASDAQ: MYL) reported Q4 EPS of $1.22, $0.05 worse than the analyst estimate of $1.27. Revenue for the quarter came in at $2.49 billion versus the consensus estimate of $2.7 billion.

GUIDANCE:

Mylan sees FY2016 EPS of $4.85-$5.15, versus the consensus of $4.90.

For earnings history and earnings-related data on Mylan (MYL) click here.

... More

Mylan (MYL) Enters Agreement to Acquire Meda in ~$9.9B Deal

February 10, 2016 4:03 PM EST

Price of SEK 165 per Meda Share at Announcement Represents a Multiple of Approximately 12.9x 2015 Adjusted EBITDA and 8.9x 2015 Adjusted EBITDA with Synergies

Strengthens Mylan's Position as a Diversified Global Pharmaceutical Leader with an Expansive and Growing Portfolio of Specialty, Generic and OTC Products and a Strong, Complementary Therapeutic Presence

Combined Business Will Have Critical Mass across Commercial Channels in Europe, a Leading U.S. Specialty Business, and an Exciting Platform for Growth in Emerging Markets

Expected to Be Immediately Accretive to Mylan Earnings, with Accretion Increasing Significantly after First Full Year (2017) as Synergies Are Realized; Creates... More